Peter DR Higgins, MD, PhD, MSc(CRDSA), AGAF
Manage Your Profile
About
Dr. Peter Higgins received his bachelor's degree and medical degrees from Duke University, and completed a Ph.D. in molecular cancer biology at Duke. He completed a fellowship in gastroenterology at the University of Michigan in 2004, completed an M.Sc. in Clinical Research Design and Statistical Analysis at the University of Michigan School of Public Health, and joined the University of Michigan faculty the same year. Dr. Higgins has previously served as the IBD editor for the American Journal of Gastroenterology, the chair of the AGA Immunology, Microbiology, and IBD section, and chaired the University of Michigan GI Division Research Advisory Council. His research focuses on inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis. He is interested in the molecular mechanisms of intestinal fibrosis, which leads to intestinal blockages and surgery. Dr. Higgins studies novel approaches to Acute Severe Ulcerative Colitis and strictures in Crohn's disease. His clinical research includes studies on patient-reported outcomes in IBD, cell therapies in IBD, and biomarker-guided therapy in IBD. Dr. Higgins' research interests are complemented by his clinical interest in improving the quality of care of patients with IBD. He served as a member of the AGA IBD Quality Measures Committee, and has participated in the development of national guidelines for high quality IBD care. Dr. Higgins currently serves as the NSAC (National Scientific Advisory Committee) chair of the Crohn's and Colitis Foundation. Dr. Higgins has received many honors and awards, including the AGA IBD Clinical Research Excellence Award.
Links
Higgins IBD Program
Center Memberships
-
Center MemberAI and Digital Health Innovation
Research Overview
Detection and measurement of inflammation in inflammatory bowel disease (IBD). Mechanisms of intestinal fibrosis, and measurement of fibrosis with ultrasound and biomarkers. Development of novel anti-fibrotic and anti-inflammatory therapies. Patient-reported outcomes in IBD.
Recent Publications
-
Guo K, Golob J, Berinstein J, Sheehan J, Chey WD, Higgins PDR, Young V, Rao K, Singh P, Bishu S, Lee A. Inflamm Bowel Dis, 2026 Nov 5;Journal ArticleMucosal transcriptomic and fecal microbiome signatures associated with persistent symptoms in quiescent Crohn's disease.
DOI:10.1093/ibd/izag244 PMID: 42986703 -
Cushing-Damm KC, Yin L, Chen Y, Oliveri A, Higgins PDR, Speliotes EK. Gastroenterology, 2026 Oct 8;Journal ArticleHLA-DRB1∗01:03 Is a Reproducible Biomarker of Colectomy Risk in Ulcerative Colitis.
DOI:10.1053/j.gastro.2026.09.017 PMID: 42849764 -
Ferrer-Torres D, Ray P, Etzioni N, Hammer MA, Ghosh A, Liu M, Jeeyar V, Wani S, Kim SS, Mungo B, Marasligiller S, Turgeon DK, Lin J, Higgins PDR, Spence JR, Lagisetty KH, Beer DG, Ray D. Cancers (Basel), 2026 Oct 6; 18 (19):Journal ArticleGSTT2 Switches from a Homeostatic Antioxidant to a Cell-Cycle-Coupled Factor in Therapy-Resistant Esophageal Adenocarcinoma.
DOI:10.3390/cancers18193220 PMID: PMC13664410 -
Herran R, Wilcox S, Hodish G, Hassan SA, Mertens H, Almario CV, Gu P, Kayal M, Cohen-Mekelburg S, Regal RE, Bishu S, Siegel CA, DeJonckheere M, Higgins PDR, Berinstein JA. Digestive Diseases and Sciences, 2026 Oct 1; 71 (10): 5037 - 5048.Journal ArticleNavigating Treatment Selection in Acute Severe Ulcerative Colitis: A Prospective Mixed Method Analysis of Factors Influencing Patient Decision-Making
DOI:10.1007/s10620-026-10046-0 PMID: 42340521 -
Torkan SO, Condray C, Li P-H, Bhatt P, Asthana A, Elbeih A, Klucevek G, Manabat AJ, Reck EC, Higgins P, Bennett A, Boden EK, Newman KL, Chedid V, Field J. The American Journal of Gastroenterology, 2026 Oct 9; 121 (10S1): s375 - s375.Journal ArticleS1724 Similar IBD Monitoring but Higher Vaccination Uptake Among Sexual and Gender Minority Adults With Inflammatory Bowel Disease: A Multicenter Matched Cohort Study
DOI:10.14309/01.ajg.0001216148.88947.02 -
Bell A, Arenberg B, Condray C, Galicia F, Ferrer D, Gilbert V, Bishu S, Berinstein J, Higgins P, Faye A, Newman KL. The American Journal of Gastroenterology, 2026 Oct 9; 121 (10S1): s416 - s416.Journal ArticleS1908 Safety and Effectiveness of Janus Kinase Inhibitors Versus Infliximab in Older Adults With Inflammatory Bowel Disease
DOI:10.14309/01.ajg.0001216884.83159.e3 -
Bhatt P, Reck EC, Elbeih A, Condray C, Li P-H, Asthana A, Klucevek G, Manabat AJ, Torkan SO, Higgins P, Bennett A, Field J, Boden EK, Newman KL, Chedid V. The American Journal of Gastroenterology, 2026 Oct 9; 121 (10S1): s428 - s428.Journal ArticleS1964 Gender-Affirming Hormone Therapy Is Linked to Fewer IBD Hospitalizations and ED Visits in Transgender and Gender Diverse Patients: A Multicenter Cohort Study
DOI:10.14309/01.ajg.0001217108.78872.3a -
Condray C, Li P-H, Torkan SO, Bhatt P, Asthana A, Elbeih A, Klucevek G, Manabat AJ, Reck EC, Higgins P, Chedid V, Field J, Bennett A, Boden EK, Newman KL. The American Journal of Gastroenterology, 2026 Oct 9; 121 (10S1): s431 - s431.Journal ArticleS1978 Sexual Minority Adults With Inflammatory Bowel Disease Have Lower Rates of Advanced Therapy Access Than Non-Sexual Minority Adults: Results of a Matched Multi-Center Cohort Study
DOI:10.14309/01.ajg.0001217164.52551.c7
Featured News & Stories